Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards to a new employee, Bill Leonard, as approved by the Company's Board of Directors' Compensation Committee. The award consists of 50,000 Performance Restricted Stock Units (PRSUs) that will vest in equal installments on December 31, 2025, 2026, and 2027. The vesting is contingent upon certain employees maintaining their employment with either Neuronetics or Greenbrook TMS Inc. through December 31, 2025. These awards were granted under the Company's 2020 Inducement Incentive Plan and comply with NASDAQ Listing Rule 5635(c)(4).
Neuronetics (NASDAQ: STIM) ha annunciato l'assegnazione di premi di indennità a un nuovo dipendente, Bill Leonard, come approvato dal Comitato per la Compensazione del Consiglio di Amministrazione dell'Azienda. Il premio consiste in 50.000 Performance Restricted Stock Units (PRSUs) che si matureranno in rate uguali il 31 dicembre 2025, 2026 e 2027. La maturazione è subordinata al fatto che alcuni dipendenti mantengano il loro impiego con Neuronetics o Greenbrook TMS Inc. fino al 31 dicembre 2025. Questi premi sono stati concessi nell'ambito del Piano di Incentivi di Induzione 2020 dell'Azienda e sono in conformità con la Regola di Quotazione NASDAQ 5635(c)(4).
Neuronetics (NASDAQ: STIM) ha anunciado la concesión de premios de inducción a un nuevo empleado, Bill Leonard, tal como fue aprobado por el Comité de Compensación de la Junta Directiva de la Compañía. El premio consiste en 50,000 Unidades de Acciones Restringidas por Rendimiento (PRSUs) que se otorgarán en cuotas iguales el 31 de diciembre de 2025, 2026 y 2027. La concesión está condicionada a que ciertos empleados mantengan su empleo con Neuronetics o Greenbrook TMS Inc. hasta el 31 de diciembre de 2025. Estos premios se concedieron bajo el Plan de Incentivos de Inducción 2020 de la Compañía y cumplen con la Regla de Cotización NASDAQ 5635(c)(4).
Neuronetics (NASDAQ: STIM)는 회사 이사회 보상위원회의 승인을 받아 새로운 직원 Bill Leonard에게 유인 상을 부여했다고 발표했습니다. 이 상은 50,000개의 성과 제한 주식 단위 (PRSUs)로 구성되어 있으며, 2025년, 2026년 및 2027년 12월 31일에 동일한 분할로 지급됩니다. 지급 조건은 특정 직원이 2025년 12월 31일까지 Neuronetics 또는 Greenbrook TMS Inc.에서의 고용을 유지하는 것입니다. 이 상은 회사의 2020 유인 인센티브 계획에 따라 부여되었으며, NASDAQ 상장 규칙 5635(c)(4)에 부합합니다.
Neuronetics (NASDAQ: STIM) a annoncé l'attribution de prix incitatifs à un nouvel employé, Bill Leonard, approuvée par le Comité de Rémunération du Conseil d'Administration de la Société. Le prix se compose de 50 000 Unités d'Actions Restreintes de Performance (PRSUs) qui seront acquises par tranches égales le 31 décembre 2025, 2026 et 2027. L'acquisition dépend du maintien de certains employés dans leur emploi auprès de Neuronetics ou de Greenbrook TMS Inc. jusqu'au 31 décembre 2025. Ces prix ont été attribués dans le cadre du Plan d'Incitation d'Induction 2020 de la Société et sont conformes à la Règle d'Inscription NASDAQ 5635(c)(4).
Neuronetics (NASDAQ: STIM) hat die Vergabe von Anreizprämien an einen neuen Mitarbeiter, Bill Leonard, bekannt gegeben, die vom Vergütungsausschuss des Unternehmensvorstands genehmigt wurde. Die Prämie besteht aus 50.000 Performance Restricted Stock Units (PRSUs), die am 31. Dezember 2025, 2026 und 2027 in gleichen Teilen fällig werden. Die Fälligkeit ist davon abhängig, dass bestimmte Mitarbeiter ihr Arbeitsverhältnis mit Neuronetics oder Greenbrook TMS Inc. bis zum 31. Dezember 2025 aufrechterhalten. Diese Prämien wurden im Rahmen des Anreizplans 2020 des Unternehmens gewährt und entsprechen der NASDAQ-Börsenregel 5635(c)(4).
- Award of 50,000 PRSUs indicates strategic employee retention efforts
- Three-year vesting schedule promotes long-term employee commitment
- Vesting conditions tied to retention of specific employees creates execution risk
- Potential future dilution from 50,000 new shares
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company’s Board of Directors and were made as material inducements to the recipients’ employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.
Performance restricted stock units (“PRSUs”)
| Name | Number of PRSUs | Vesting Date |
| Bill Leonard | 50,000 | (see below) |
The PRSUs will vest in substantially equal installments on December 31, 2025, December 31, 2026, and December 31, 2027, but only if certain employees do not terminate their employment with the Company or Greenbrook TMS Inc., as applicable, on or before December 31, 2025.
About Neuronetics and Greenbrook
Neuronetics, Inc. (“Neuronetics”) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations by offering exceptional treatments that produce extraordinary results. Neuronetics’ NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
How many PRSUs did Neuronetics (STIM) grant to Bill Leonard in December 2023?
What are the vesting dates for Neuronetics' (STIM) newly granted PRSUs?
What are the conditions for STIM's PRSU vesting announced in December 2023?
Under which plan were Neuronetics' (STIM) inducement awards granted?
